Clinical Trial Update: Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection [Phase 1]

View source ↗

Summary

This entry reports the completion of a Phase I trial evaluating the safety, tolerability, and immunogenicity of VGX-6150 as second-line therapy for chronic hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• VGX-6150

Snippet

Sponsor: GeneOne Life Science, Inc. | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED